<div id="readability-page-1"><p>LifeSci Capital analyst Sam Slutsky maintained a Buy rating on CG Oncology, Inc. today and set a price target of $108.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Palvella Therapeutics, and Enliven Therapeutics. According to TipRanks, Slutsky has an average return of <span>44.6%</span> and a 52.24% success rate on recommended stocks. </p> <p>In a report released on May 14, Bank of America Securities also maintained a Buy rating on the stock with a $83.00 price target.</p></div>

CGON

SBIO

IBBQ

LABU

<p>LifeSci Capital analyst Sam Slutsky has maintained a Buy rating on CG Oncology, Inc. (CGON) with a price target of $108.00. Slutsky, who focuses on the Healthcare sector, has an average return of 44.6% and a 52.24% success rate on recommended stocks. Additionally, Bank of America Securities also maintained a Buy rating with a price target of $83.00.</p>

Tip Ranks

CG oncology

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

CG Oncology, Inc. (CGON) Receives a Rating Update from a Top Analyst